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The purpose of this study was to quantify the stem cell and growth factor (GF) contents in the bone marrow aspirate concentrate
(BMAC) and platelet-rich plasma (PRP) prepared from whole blood using a protocol established in our laboratory. We examined
10 patients with osteonecrosis of the femoral head who were treated by autologous BMAC transplantation at our hospital between
January 2015 and June 2015. We quantified CD34+ and CD31−CD45−CD90+CD105+ cells in BMAC and PRP by flow cytometry.
Additionally, we measured various GFs, that is, basic fibroblast growth factor (b-FGF), platelet-derived growth factor-BB (PDGF-
BB), vascular endothelial growth factor (VEGF), transforming growth factor-𝛽1 (TGF-𝛽1), and bone morphogenetic protein-2
(BMP-2) in BMAC and PRP using enzyme-linked immunosorbent assays and statistical analyses. CD34+ and CD31−45−90+105+
cells accounted for approximately 1.9% and 0.03% of cells in BMAC and no cells in PRP. The concentration of b-FGF was higher
in BMAC than in PRP (𝑃 < 0.001), whereas no significant differences in the levels of PDGF-BB, VEGF, TGF-𝛽1, and BMP-2 were
observed between the two types of sample. BMAC had an average of 1.9% CD34+ and 0.03% CD31−45−90+105+ cells and higher
levels of b-FGF than those of PRP.
1. Introduction
Bone marrow aspirate (BMA) is a mixture of aspirated BM
cells, small tissue fragments, and venous sinus blood (periph-
eral blood). Its bone-stimulating effects were first described
in experiments using rabbits [1]; it was later discovered
that fibroblast-like cells with adhesive, colony-forming, and
osteogenic potential are present in BM [2]. It is now known
that mesenchymal stem cells in the BM have the potential
to differentiate into various mesenchymal tissues [3]. BMAs
have been used in orthopedic surgery for nonunion [4], the
treatment of osteonecrosis (especially femoral head necrosis)
and osseous defects, and bone lengthening [5–8].
We previously developed a treatment for osteonecrosis
and nonunion using 30–40ml of BMA concentrate (BMAC)
produced without special instruments from 300–400ml of
BMAs harvested from the ilium and centrifuged [9–14]. To
ensure that the buffy coat layer of the BMA was extracted
without leakage, the areas immediately above and below this
layer were also manually extracted. Thus, the BMAC also
contained the platelet-rich plasma (PRP) formed just above
the buffy coat layer. This fraction, which is a plasma fraction
containing an abundance of platelets, has clinical applica-
tions in the field of orthopedic surgery as a regenerative
treatment, primarily for sports injuries [15, 16]. Our earlier
studies demonstrated the therapeutic value of PRP obtained
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from whole peripheral blood (WB) [16, 17]. Transplanting
BMAC and PRP together also has positive results [18, 19].
However, BMAC and PRP preparation methods vary from
one experiment to the next; as such, there are no conclusive
results regarding differences between cellular components
and humoral factors contained in BMAC or PRP.
To address this issue, we analyzed the stem cell and
growth factor contents of the BMAC produced using our
protocol. Specifically, we quantified hematopoietic progeni-
tor/stem cell andmesenchymal stromal/stem cell populations
as well as growth factor concentrations. We also evaluated
differences in the compositions of BMAC and PRP prepared
fromWB.
2. Materials and Methods
All procedures were approved by the Institutional Ethics
Review Committee of the University of Tsukuba. Informed
consent was obtained preoperatively from all study partici-
pants.
2.1. Patients. Ten patients with osteonecrosis of the femoral
head (ONFH) who were treated by concentrated autologous
BMA transplantation at our hospital between January 2015
and June 2015 were included. The mean age of the eight male
patients and two female patients was 40 years (range: 28–59
years). In this cohort, ONFH developed in eight patients
following long-term corticosteroid use and in two patients
who abused alcohol.
2.2. BMAspiration and Concentration. BMwas aspirated and
concentrated according to a previously published method
[9–14]. Briefly, patients were given general anesthesia and
BM was aspirated from both anterior iliac crests using a BM
harvest needle (Medical Device Technologies, Gainesville,
FL, USA) with 20ml syringes prefilled with 1.5ml of the
anticoagulant citrate dextrose. Aspirates were collected using
a BM collection kit (Baxter, Deerfield, IL, USA) and then
transferred to a quadruple blood bag (Terumo, Tokyo,
Japan) for concentration by a two-step centrifugationmethod
(KUBOTA 9800; Kubota, Tokyo, Japan). The blood bag
contents were first centrifuged at 1200×g for 10min at room
temperature, and erythrocytes were removed from the origi-
nal bag. The remaining contents were centrifuged at 3870×g
for 7min at room temperature, after which the plasma and
anticoagulants were removed followed by extraction of the
BMAC containing the buffy coat.This technique reduced the
400ml volume of BMA to 30–40ml of BMAC, of which 4ml
was used for experiments.
2.3. Preparation of PRP Derived fromWB. At the time of BM
aspiration and concentration, 18ml ofWBwas obtained from
the same patient. PRP was prepared from WB as previously
described [20]. A 21-gauge butterfly needle was used to draw
18ml of WB from the cubital vein of the subjects, while
avoiding hemolysis. The blood was collected in two 9ml
Spitz tubes containing 3.8% citric acid and was centrifuged
at 580×g for 8min at room temperature (PRGF-Endoret
IV System; BTI Biotechnology Institute, Vitoria, Spain). The
contents of each tube were separated into the erythrocyte,
buffy coat, and plasma layers. In the separated plasma layer,
a safety area was delineated in the upper area of the buffy
coat, while avoiding aspirating the buffy coat; the upper and
lower halves of the plasma layer were defined as platelet-poor
plasma and PRP, respectively. About 2ml of PRP per Spitz
tube was collected by aspiration using a dedicated aspirator
(PRGF-Endoret IV; BTI Biotechnology Institute) for a total
of about 4ml of PRP from the two tubes.
2.4. Hematological Analysis. Nucleated white blood cells and
platelets in BMA, BMAC, WB, and PRP were counted using
an automated system (Sysmex KX-21N; Sysmex Corp., Kobe,
Japan).
2.5. Fibroblastic Colony-Forming Unit (CFU-F) Assay and Cell
Characterization. To determine the presence and proportion
of progenitor cells in BMA and BMAC, samples from each
patient were evaluated with the CFU-F assay, as previously
described [10, 12, 14].The samples (100 𝜇l) were washed twice
with phosphate-buffered saline and then resuspended in 3ml
of growth medium composed of Dulbecco’s Modified Eagle’s
Medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum (Gibco, Grand Island, NY, USA)
and antibiotic–antimycotic solution (Gibco). The cells were
seeded in 60 cm2 dishes and cultured at 37∘C in a humidified
atmosphere of 5% CO2. The medium was replaced 2 days
later and nonadherent cells were removed; thereafter, the
medium was replaced twice a week. After 2 weeks, the
medium was removed and cells were stained with 0.5%
Crystal Violet (Sigma-Aldrich) in methanol for 5min and
washed twice with distilled water before the number of CFU-
Fs was counted. Colonies of <2mm in diameter and those
that were only faintly stained were excluded. The number of
progenitor cells is expressed as the number of CFU-Fs per 106
nucleated cells.
In order to analyze the cellular composition of BMAC, the
number of CD34+ cells, which are precursors of hematopoi-
etic cells, and CD31−45−90+105+ cells were determined.
BM cells in BMAC were incubated in red blood cell lysis
buffer (VersaLyse; Beckman Coulter, Brea, CA, USA) at 37∘C
for 5min, followed by incubation for 30min at 4∘C with
fluorescein isothiocyanate-conjugated anticluster of differen-
tiation (CD)31 (1 : 40), phycoerythrin (PE)/Cy5-conjugated
anti-CD90 (1 : 200), energy-coupled dye (PE-Texas Red)-
conjugated anti-CD45 (1 : 40), and allophycocyanin- (APC-)
conjugated anti-CD105 (1 : 200) antibodies (all from BD
Pharmingen, San Jose, CA, USA), and APC-conjugated anti-
CD34 antibody (1 : 200; Biolegend, San Diego, CA, USA).
Matching isotype control antibodies were used as a control.
After incubation, labeled cells were sorted on a Gallios flow
cytometer (Beckman Coulter), and data were analyzed using
Kaluza software (Beckman Coulter).
2.6. Growth Factor (GF) Quantification. TheBMAC and PRP
were incubated at 37∘C for 1 h after adding 5% calcium
chloride (BTI Biotechnology Institute) and centrifuged at
1000×g for 20min at 4∘C. The supernatant was removed
and stored at −80∘C. The cryopreserved supernatant was
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thawed at room temperature before use. The concentrations
of basic fibroblast growth factor (b-FGF), platelet-derived
growth factor- (PDGF-) BB, transforming growth factor-
(TGF-) 𝛽1, vascular endothelial growth factor (VEGF), and
bonemorphogenetic protein- (BMP-) 2 weremeasured using
enzyme-linked immunosorbent assay kits specific for each
GF (R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s recommendations. All standards and samples
were analyzed in duplicate.
2.7. Statistical Analysis. The numbers of nucleated cells and
platelets in BMAC and PRP before and after the concen-
tration procedure were analyzed using Wilcoxon’s rank sum
tests. The GF quantification results for BMAC and PRP
were analyzed using Mann–Whitney 𝑈 tests. 𝑃 < 0.05 was
considered statistically significant. Analyses were performed
using IBM SPSS Statistics v.24.0 (IBM Corp., Armonk, NY,
USA).
3. Results
3.1. Characterization of Cells in BMAC and PRP. The volume
of BMA obtained was 402 ± 35ml; after concentration, the
volume was 35.4 ± 1.6ml. The average ratio of the volumes
after and before concentration was 11.4. The findings of the
hematological analysis are presented in Figure 1. On average,
the number of nucleated cells was 5.53-fold higher in BMAC
(43.0 ± 15.1 × 103/𝜇l) than in WB (7.78 ± 3.06 × 103/𝜇l), and
BMAC had higher levels of WBC than BMA (𝑃 < 0.001).
The average platelet count was also 5.93-fold higher in BMAC
(38.1± 21.1 × 104/𝜇l) than in BMA (6.42±3.06 × 104/𝜇l) and
BMAC had higher levels of PLT than BMA (𝑃 < 0.001). No
nucleated cells were detected in PRP samples. The average
platelet count was 1.49-fold higher in PRP (28.8 ± 11.6 ×
104/𝜇l) than inWB (19.3±4.04 × 104/𝜇l) and PRP had higher
levels of PLT than WB (𝑃 = 0.049). Based on platelet counts
and the presence of white blood cells and neutrophils, the
PRP preparation was classified as P2-x-B𝛽 according to the
platelet-activation white blood cell classification system [21].
The mean CFU-F count in BMAC (196 ± 161/ml) was
higher than that in BMA (31.6 ± 37.0/ml). The mean
concentration rate of CFU-F was 6.0 ± 4.4, and the number
of CFU-F per 106 nucleated cells in BMAC was 4.62 ± 4.07.
The mean percentage of CD34+ cells per total BM cells
was 1.87% (range: 0.60%–4.25%), and the mean percentage
of CD31−45−90+105+ cells per total BM cells was 0.030%
(range: 0.001%–0.101%) (Figure 2).
3.2. GF Levels in BMAC and PRP. GF levels in BMAC were
as follows: b-FGF, 6.78 ± 5.87 × 101 pg/ml; PDGF-BB, 5.28 ±
2.57 × 103 pg/ml; VEGF, 1.76 ± 1.18 × 102 pg/ml; TGF-𝛽1,
1.56 ± 1.33 × 104 pg/ml; and BMP-2, 9.99 ± 0.59 × 101 pg/ml.
The levels in PRP were as follows: b-FGF, 1.07 ± 0.35 ×
101 pg/ml; PDGF-BB, 6.71 ± 4.21 × 103 pg/ml; VEGF, 2.39 ±
2.11 × 102 pg/ml; TGF-𝛽1, 2.65±1.46 × 104 pg/ml; and BMP-
2, 9.87 ± 0.50 × 101 pg/ml. The concentration of b-FGF was
higher in BMAC than in PRP (𝑃 < 0.001), whereas no
significant differences in the levels of the other GFs were
observed between the two types of sample (Figure 3). GF
levels for each patient are presented in Figure 4.
4. Discussion
CD34+ and CD31−45−90+105+ cells accounted for approx-
imately 1.9% and 0.03% of cells in BMAC, respectively.
BMAC contained a higher concentration of b-FGF than PRP,
although the two types of sample had similar concentrations
of the other GFs. It was previously demonstrated that CD34+
positive cells make up about 1% of the total number of
mononuclear cells [22]; other investigators have reported
that the proportion of nucleated cells in BMAC that were
CD34+ was 1.0% ± 0.2% [23], which is consistent with our
observations.
CFU-Fs constitute 0.01%–0.001% of all BMmononuclear
cells [24], corresponding to a mesenchymal stem cell (MSC)
ratio of 1/100,000 hematopoietic cells [25]. Although the
average number of CD31−45−90+105+ cells was relatively
high (0.03%), the average number of CFU-Fs was small
(4/106 mononuclear cells). Other investigators have obtained
results similar to those of the present study using the
same BMAC preparation method, with an average num-
ber of CFU-Fs of 2.55/106 mononuclear cells [14]. On the
other hand, a CD45−CD271+ cell fraction of 0.016% (from
0.009%–0.032%) was observed in BMAs, with 1520 cells per
1ml of BM (96–20,992) and a significantly lower average
CFU-F count, that is, 60 (3–900) per 1ml of BM [26] or
comparable results [27, 28]. In the present study, we also
obtained a high cell count based on an analysis of cell surface
antigen expression as compared to CFU-F.
To measure GF levels in BMAC and PRP, 5% calcium
chloride was added to both samples, that is, BMAC and PRP,
for platelet activation. Sa´nchez et al. reported that calcium
chloride leads to platelet activation and the hydrolysis of
prothrombin into thrombin, which simultaneously causes the
release of myriad growth factors and the polymerization of
fibrin [20].
A comparison of GF levels in BMAC and WB PRP
revealed no significant differences in PDGF, TGF-𝛽1,
interleukin- (IL-) 8 or interleukin-6, tumor necrosis factor-𝛼,
interferon-𝛾, or FGF-1 levels; however, VEGF and IL-1
receptor antagonist levels were higher in BMAC than in
PRP [29]. We found similar results for PDGF and TGF-𝛽1
but observed no significant differences in VEGF expression,
whereas b-FGF was elevated in BMAC as compared to PRP.
VEGFmodulates angiogenesis, migration, and mitosis of
endothelial cells as well as the creation of the blood vessel
lumen [30, 31]. The PRP VEGF concentration of 2.39 ±
2.11 × 102 pg/ml obtained here is comparable to the value
of 2.76 ± 2.73 × 102 pg/ml found in a previous study [29].
However, others have reported VEGF concentrations in PRP
of 76–854 pg/ml [30] and 10 ± 12 pg/ml [29]. Moreover,
we found a BMAC VEGF concentration of 1.76 ± 1.18 ×
102 pg/ml, which is higher than that reported by Cassano
et al. [29], but comparable to the results of Alsousou et al.
[30] (Table 1). Our data suggest that PRP and BMAC contain
equivalent amounts of VEGF. However, given that this is
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Figure 1: Numbers of nucleated cells and platelets in BMAC and PRP before and after concentration. (a) BMAC had higher levels of WBC
than BMA (𝑃 < 0.001). (b) BMAC had higher levels of PLT than BMA (𝑃 < 0.001). (c) No nucleated cells were detected in PRP samples. (d)
PRP had higher levels of PLT than WB (𝑃 = 0.049). (∗𝑃 < 0.05).
contradicted by other reports, a more detailed analysis of a
larger number of cases is warranted.
FGF belongs to a family of heparin-binding polypeptide
GFs that includes b-FGF (FGF-2), which activates signaling
pathways involved in the development and maintenance of
cartilage [32]. b-FGF is known to induce cell proliferation
and chondrogenic differentiation in human BM MSCs [33].
However, there are no studies of b-FGF concentrations in
BMAC; in one study, FGF-1 was not detected in BMAC or
PRP [29], but b-FGF was not evaluated. We found that b-
FGF was present at higher concentrations in BMAC than in
PRP.
b-FGF is involved in the maintenance of the MSC
cytoplasmic volume and spindle morphology [34–36]. MSCs
cultured with FGF maintained the spindle shape typical of
fibroblasts, whereas, in the absence of FGF, cells developed
a large cytoplasmic volume [34]. Identical results were
obtained for MSCs derived from human BMAs [35–37]. In
this study, we found MSCs in BMAC, but not in PRP, and
observed higher concentrations of b-FGF in BMAC; however,
it remains to be determined whether b-FGF plays a role in
maintaining MSC cell morphology.
Using our method, leukocytes were not detected in PRP,
and the platelet counts in PRPwere lower than those for other
Bone Marrow Research 5
CD45
CD
34
103
102
101
100
103102101100
CD34: 0.73%
2.03
0.00
97.23
0.73
% gated
100.00
4,040
7
193,078
1,445
Number
198,570
Gate
All 
V−−
V−+
V+−
V++
(a)
CD31
CD
45
CD90
CD
10
5
103
102
101
100
103102101100 10
3102101100
103
102
101
100
2.21
% gated
100.00
16,062
Number
726,569
Gate
All 
Y 2.37
% gated
100.00
381
Number
16,062
Gate
All 
AA
(b)
Figure 2: Flow cytometry results for CD34+ cells and CD31−45−90+105+ cells. Results for a 37-year-old woman with corticosteroid-induced
ONFH. (a) The percentage of CD34+ cells per total BM cells was 0.73% (1,452/198,570). (b) The percentage of CD31−45−90+105+ cells per
total BM cells was 0.052% (381/726,569).
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Figure 3: GF levels in BMAC and PRP. (a) BMAC had higher levels of b-FGF than PRP (𝑃 < 0.001). (b–e)There were no differences between
PRP and BMAC in terms of PDGF-BB, VEGF, TGF-𝛽1, and BMP-2 levels. (∗𝑃 < 0.05).
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Figure 4: GF levels for each patient. (a) BMAC; (b) PRP.
Table 1: Comparison of VEGF levels in BMAC and PRP.
VEGF level (pg/ml)
BMAC PRP
Our study 239 ± 211 176 ± 118
Cassano et al. [29] 276 ± 273 10 ± 12
Alsousou et al. [30] - 76 to 854
methods. Some studies have reported platelet or leukocyte
counts in PRP and GF levels. In PRP prepared using five
different systems, Magalon et al. found positive correlations
between platelet counts in PRP and levels of VEGF, PDGF-
AB, and TGF-𝛽1 and between leukocyte counts in PRP and
levels of VEGF [38]. Zimmermann et al. reported remarkable
interindividual variation in GF levels and no correlation
between GF levels and platelet concentration [39]. Castillo
et al. reported a positive correlation between GF levels and
leukocyte counts in PRP [40]. Our method might have a
disadvantage with respect to GF levels in PRP owing to the
relatively low enrichment for platelets.
These findings are applicable to the procedures and
instruments that we developed to obtain BMAC and PRP;
similar tests, including comparative analyses, should be per-
formedwhen othermethods are used for sample preparation.
One limitation of this study was the small sample size. For
patients with ONFH, blood sampling to obtain PRP was
not directly related to their treatment and accordingly the
number of samples was limited. Furthermore, since BMAC
and PRP preparation methods can vary, caution must be
exercised when comparing the results of different studies.
5. Conclusion
We produced BMAC that contained an average of 1.9%
CD34+ and 0.03% CD31−45−90+105+ cells. BMAC had
higher levels of b-FGF than PRP, although the two samples
had comparable levels of PDGF-BB, VEGF, TGF-𝛽1, and
BMP-2. These findings suggest that our protocol can be used
to produce BMAC for therapeutic applications, such as the
treatment of osteonecrosis and nonunion.
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